Toripalimab and fruquintinib therapy for colorectal cancer after failed multiline chemotherapies: a case report

The options for treating metastatic colorectal cancer are limited after failure of second-line chemotherapy. In this case report, we present the outcome of a 59-year-old male patient who underwent radical resection for rectal cancer in November 2018 and hepatectomy for liver metastasis in January 2021. His metastatic rectal cancer presented a remarkable response to the combination of fruquintinib and toripalimab after the failure of multiline chemotherapies. The patient achieved partial response within 3 months and clinical complete response of pulmonary masses within 12 months. As of now, the patient maintains a good quality of life, and the progression-free survival has been more than 17 months. In conclusion, the combination of fruquintinib and PD-1 inhibitors can improve the prognosis of metastatic colorectal cancer. The available antitumor treatment options are very limited for patients with advanced colorectal cancer (a type of colon cancer), especially after multiple treatments have already failed. Often for patients in this situation, the available treatments do not work very well and the patients are not predicted to live very long. However, in this paper we report a case of successful treatment of this condition. A 59-year-old male patient with advanced colorectal cancer was treated with the combination therapy of two different immunotherapy drugs, fruquintinib and toripalimab, after multiple other treatments had failed. Currently, the survival time of this patient is over 17 months, and he has a satisfactory quality of life.

Automated summary

Treatment options for metastatic colorectal cancer are limited after second-line chemotherapy failure. In this case report, a 59-year-old male patient achieved remarkable response to fruquintinib and toripalimab combination therapy after multiple lines of chemotherapy failed. The patient had partial response within 3 months and complete response of pulmonary masses within 12 months. The combination of fruquintinib and PD-1 inhibitors improves the prognosis of metastatic colorectal cancer, with a progression-free survival of over 17 months.